Aura Biosciences (NASDAQ:AURA - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09), Zacks reports.
Aura Biosciences Stock Up 6.7 %
NASDAQ:AURA traded up $0.40 during mid-day trading on Friday, reaching $6.34. 3,115,195 shares of the company were exchanged, compared to its average volume of 189,867. The stock has a market cap of $316.69 million, a PE ratio of -3.66 and a beta of 0.30. Aura Biosciences has a 12 month low of $5.77 and a 12 month high of $12.38. The company has a fifty day moving average of $7.54 and a 200 day moving average of $8.60.
Insider Buying and Selling
In related news, insider Los Pinos Elisabet De sold 15,955 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 23,045 shares of company stock worth $177,242 in the last quarter. Insiders own 5.40% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on AURA. Lifesci Capital upgraded shares of Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. HC Wainwright reaffirmed a "buy" rating and set a $22.00 price objective on shares of Aura Biosciences in a report on Monday, March 24th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Aura Biosciences presently has an average rating of "Buy" and an average target price of $23.00.
Get Our Latest Report on Aura Biosciences
Aura Biosciences Company Profile
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Recommended Stories
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
